S'abonner

Clinical course and risk factors of mortality in Mycobacterium avium complex lung disease without initial treatment - 09/09/20

Doi : 10.1016/j.rmed.2020.106070 
Ping-Huai Wang a, b, Sheng-Wei Pan c, d, Chin-Chung Shu e, f, , Chung-Yu Chen f, g, Yu-Feng Wei h, i, Shih-Lung Cheng a, j, Hao-Chien Wang e, f, Chong-Jen Yu e, f
a Division of Pulmonology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan 
b Department of Nursing, Oriental Institute of Technology, Taiwan 
c Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan 
d School of Medicine, National Yang-Ming University, Taipei, Taiwan 
e Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan 
f College of Medicine, National Taiwan University, Taipei, Taiwan 
g Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan 
h School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan 
i Division of Chest Medicine, Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan 
j Department of Chemical Engineering and Materials Science, Yuan-Ze University, Taiwan 

Corresponding author. Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei City, Taiwan.Department of Internal MedicineNational Taiwan University HospitalNo. 7Chung-Shan South RoadTaipei CityTaiwan

Abstract

Purpose

Mycobacterium avium complex-lung disease (MAC-LD) is increasing worldwide and may progress to cause mortality significantly. However, for patients without initial treatment at diagnosis, the survival outcomes and predictors of mortality remain unclear.

Methods

From 2011 to 2017, MAC-LD patients at two medical centers in Taiwan were screened, and those who received MAC treatment at the initial were excluded. The clinical course and characteristics were recorded. Cox regression analysis and receiver operating characteristic (ROC) curves were performed to assess risk factors of mortality within 4 years.

Results

We included 123 MAC-LD patients without initial MAC treatment. The mean follow-up period was 4.15 ± 2.52 years. Twenty-two (17.9%) patients died within four years. Multivariate analysis showed that four independent factors related to 4-year mortality were consolidation pattern (hazard ratio [HR] 6.0, 95% confidence interval [2.3–15.5]), radiographic score > 6 (HR:11.0 [4.0–31.1]), radiographic deterioration within two years (HR: 5.2 [2.1–13.1]) and no MAC treatment during follow up (HR: 6.5 [1.3–31.1]). The areas under the ROC curves for prediction of 4-year mortality for the combination of consolidation and radiographic score >6, the two factors plus radiographic progression, the two plus no MAC treatment, and the combination of the four factors were 0.702, 0.798, 0.758, and 0.835, respectively.

Conclusions

The four-year mortality rate in MAC-LD without initial treatment is high. Presence of consolidation pattern and radiographic score >6 at initial visit, radiographic deterioration and no treatment during follow-up were risk factors of 4-year mortality in initially untreated MAC-LD.

Le texte complet de cet article est disponible en PDF.

Highlights

Four-year mortality rate is notable in those without initial MAC treatment.
Consolidation and radiographic score initially are risk factors for mortality.
Radiographic deterioration within two years is associated with four-year mortality.
No timely treatment and the above three factors together are highly risky for mortality.

Le texte complet de cet article est disponible en PDF.

Keywords : Radiographic, Mycobacterium avium complex, MAC, Lung disease, Outcome


Plan


© 2020  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 171

Article 106070- septembre 2020 Retour au numéro
Article précédent Article précédent
  • Diagnostic utility of endobronchial ultrasound (EBUS) features in differentiating malignant and benign lymph nodes - A systematic review and meta-analysis
  • Sumita Agrawal, Akhil Dhanesh Goel, Nitesh Gupta, Ayush Lohiya, Hari Kishan Gonuguntla
| Article suivant Article suivant
  • Clinical significance of anti-glycopeptidolipid-core IgA antibodies in patients newly diagnosed with Mycobacterium avium complex lung disease
  • Shuichi Matsuda, Takanori Asakura, Kozo Morimoto, Shoji Suzuki, Keiji Fujiwara, Koji Furuuchi, Takeshi Osawa, Ho Namkoong, Makoto Ishii, Atsuyuki Kurashima, Koichiro Tatsumi, Ken Ohta, Naoki Hasegawa, Yuka Sasaki

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.